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Resumo
Introdução: Os inibidores da bomba de protões (IBPs) são utili-
zados no tratamento da patologia gastrointestinal e prevenção 
da hemorragia digestiva alta, frequentemente de forma inade-
quada nos doentes hospitalizados. 
Métodos: Realizou-se um estudo transversal entre 15 de Março 
e 15 de Maio de 2015 para avaliar o padrão de prescrição de 
IBPs num Serviço de Medicina Interna, relativamente às indica-
ções e aos custos. 





dicados de forma inapropriada. Os predictores de prescrição 
inadequada	de	IBP	foram	o	sexo	feminino,	idade	≥	75	anos	e	
estar medicado com IBP pré-admissão. 
Conclusão: Custos totais, directamente relacionados aos IBPs, 
ascenderam	aos	€1079,96,	em	média	€2,72	por	episódio.	A	te-
rapêutica com IBPs deve ser revista para reduzir prescrições 
inadequadas e custos.




Proton pump inhibitors (PPIs) are widely used for several primary 
gastrointestinal	disorders	(dyspepsia,	gastroesophageal	reflux	
disease (GERD), peptic ulcer disease, Helicobacter pylori era-
dication, others)1-6 as well as in prevention of upper gastrointesti-
nal bleeding (UGIB) such as in the context of antiplatelet therapy 
or	non-steroidal	anti-inflammatory	drugs	(NSAID)	therapy.7-10 Its 
widespread	use	reflects	PPIs	overall	efficacy	and	safety.	Howe-
ver, some of the risks linked to PPI use include higher rates of 
enteric infections including Clostridium difficile, community-ac-
quired pneumonia, hip fractures, drug interactions (clopidogrel, 
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although	inconsistent	through	PPIs)	and	several	nutritional	defi-
ciencies.11-15 Large scale unmonitored use of PPIs may enhance 
these iatrogenic risks.
Internal Medicine (IM) patients are some of the most pro-
ne to receiving a PPI prescription, either from their general 
practitioners, when hospitalized in IM wards or at the time 
of hospital discharge.12-19 Appropriate prescription of PPI on 
hospital admission is generally limited to patients with UGIB, 
peptic ulcer or erosive esophagitis and in a subset of Intensi-
ve Care Unit (ICU) patients.1 It is then arguable that many pa-
tients admitted to IM wards are inappropriately prescribed a 
PPI, leading to iatrogenic and economic consequences.1,20,21 
PPI prescription itself is not the only problem as a reasonable 
number of patients are inappropriately prescribed intrave-
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nous forms, usually reserved for active UGIB.22-24
The purpose of this research was to evaluate prescription pa-




An observational cross-sectional study was conducted from 
15th March 2015 to 15th May 2015 in the Internal Medicine (IM) 
department at Hospital Central do Funchal, SESARAM EPE, 
Funchal, Portugal, a tertiary hospital with 134 IM beds. Conse-
cutive admissions to the general ward and intermediate care 
unit were enrolled. Exclusion only happened when there was 
discrepancy	between	patient	file	number	and	patient	name.	
Demographic data was obtained (sex, age). Motive of admis-
sion was noted and categorized in six groups according to 
higher prevalence in the sample (lower respiratory tract infec-
tions (LRTIs), urinary tract infections (UTIs), heart failure (HF), 
ischemic stroke (IS), cerebral hemorrhage (CH) and others) 
as seen on Table 1. Relevant ambulatory medications were 
also	 enquired	 (antiplatelet	 therapy,	 anticoagulants,	 NSAID,	
corticosteroids). Daily therapeutic online sheets were consul-
ted for prescription data extraction (date of initiation, date of 
suspension, administration route, date of change of adminis-
tration route, and type of PPI). For information regarding the 
use of PPI prior to admission and the motive for such use, 
each	patient	file	was	reviewed	in	search	of	diagnosed	entities	
and endoscopic data in the year prior to ward admission. We 
considered a positive history if the PPI was prescribed within 
the last year before admission date. Data regarding ambu-
latory prescription at time of discharge were obtained from 
discharge note and reason for prescription was evaluated. If 
a patient was admitted more than once during the research 
period they were enrolled as a separate episode. Our aim 
was to assess physician prescription behavior with each new 
episode. Moreover, patient distribution per attending physi-
cian on admission is random, hence a readmission could be 
delivered to a different physician, yielding a different pres-
cription outcome. Department director was informed of stu-
dy but not the remaining physicians in order to assess PPI 
prescription knowledge at baseline. A follow-up study after 
presentation of results and literature review is scheduled to 
assess intervention impact.
Valid criteria for preventive PPI usage in inpatient setting 
and at discharge time are guidelines updated at time of this 
study, which are described elsewhere.1-10 Main outcome was 
appropriateness of PPI usage among IM inpatients according 
to current evidence. Some considerations should be taken 
into account regarding criteria used: Intravenous (IV) PPIs 
are not indicated for UGIB prophylaxis. In all cases, oral or 
enteric formulas should be used. IV formulas are reserved for 
peptic ulcer disease in the context of endoscopic procedures 
or	after	an	endoscopic	procedure	 that	confirms	a	bleeding	
ulcer or a non-varicose lesion with a high risk for bleeding re-
currence.18 In the case of GERD, PPIs are only recommended 
for: recurring or severe symptomatic GERD as maintenance 
therapy or induction and maintenance therapy of erosive eso-
phagitis	and	finally	for	maintenance	therapy	for	Barrett’s	eso-
phagus. Duration of therapy should be individualized in all 
cases.17 In the case of peptic disease, PPIs are recommend 
for induction and maintenance therapy for high risk gastric 
ulcers (hemorrhage, perforation, refractory, recurrent, giant 
and	fibrotic)	as	well	as	duodenal	ulcers.17 In this study, chro-
nic corticosteroid therapy refers to a therapy duration supe-
rior to three weeks.10
Finally, a simple economic analysis was performed in order 
to obtain the total amount spent on inappropriate use. Me-
dical	 records	were	reviewed	by	authors	(LRS	and	SN).	The	
study was conducted in adherence with the Declaration of 
Helsinki and approved by the institution’s Ethical Committee.
Statistical analysis was performed using SPSS software, 
version 19. Descriptive analysis was initially performed. Chi-
-square and Fischer’s exact test were used for analysis of 
categorical variables while continuous variables were evalua-
ted using student’s t-test. Logistic regression was conducted 
with	statistically	significant	variables	from	univariate	analysis	
as	well	as	some	non-significant	but	considered	 relevant	 for	
the	 study;	 odds	 ratio	 (OR)	 and	 respective	 95%	confidence	
intervals	 (CI)	were	 calculated.	 Significance	was	defined	as	
p < 0.05.
Figure 1: Flowchart on the selection of patients in the study.
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Table 1: Univariate analysis PPI inpatient and discharge prescription
Variable
 PPI admission 
prescription 
No, n (%)
Yes, inappropriate, n (%) Total n = 522 p-value
Sex Female 111 (52.1) 194 (62.8) 305 0.015
Male 102	(47.9) 115	(37.2) 217
Age (years) ≤	65	years 57	(26.7) 40 (12.9) 97  
 66-74	years 43 (29.2) 60 (19.4) 103 0.000
 ≥	75	years 113 (53.1) 209	(67.6) 322  
Motive of admission  213 (100) 309 (100) 522 0.085
Place of admission General ward 205 (96.2) 295 (95.5) 500 0.665
 Intermediate Care Unit 8 (3.8) 14 (4.5) 22  
Prior to admission PPI No 189	(85.7) 211 (68.3) 400 0.000
 Yes 24 (11.3) 98	(31.7) 122  
 0-3 106 (49.8) 141 (45.6) 247  
Number	of	admission		
comorbidities 4-6 95 (44.6) 147	(47.6) 24 0.617








Yes, inappropriate, n (%)  Total n = 278 p-value
Sex Female 118 (62.4) 65	(73.0) 183 0.082
 Male 71	(37.6) 24	(27.0) 95  
Age (years) ≤	65	years 37	(19.6) 3 (3.4) 40  
 66-74	years 40 (21.2) 15 (16.9) 55 0.000
 ≥	75	years 112 (59.3) 71	(79.8) 183  
Motive of admission  129 (100) 89 (100) 278 0.295
Place of admission General ward 178	(94.2) 87	(97.8) 265 0.236
 Intermediate Care Unit 11 (5.8) 2 (2.2) 13  
Prior to admission PPI No 179	(94.7) 14	(15.7) 193 0.000
 Yes 10 (5.3) 75	(84.3) 85  
 0-3 91 (41.8) 21 (23.6) 112  
Number	of	discharge		
comorbidities 4-6 90	(47.6) 55 (61.8) 145 0.000
 7-9 8 (4.2) 13 (14.6) 21





Three hundred seventy-two admissions were female patients 
(59.5%).	Patient	mean	age	was	75	years	(SD	14.62)	with	a	range	
between 18-100 years. Top three admission motives were LRTIs, 
UTIs	and	HF	with	45.8,	12.0	and	10.9%,	respectively.	54.6	%	of	




the	general	 IM	ward	while	26	(4.4%)	received	treatment	 in	 the	
intermediate	 care	 unit.	 One	 hundred	 and	 sixty-three	 (27.9%)	




on admission or during inpatient stay. When reviewing medical 
record and daily therapeutic sheets just 63 cases had a proper 
indication for inpatient PPI prescription (each patient could have 
more	than	1	indication)	which	means	that	309	episodes	(83.1%)	
were inappropriately medicated.
Table 1 shows univariate analysis for PPI prescription on ad-
mission, comparing patients who did not receive a PPI versus pa-
tients	who	received	an	inadequate	prescription	(n	=	522).	Female	
sex, increasing age group and prior PPI use showed statistically 
significant	differences	in	this	study,	highlighting	these	variables	
as factors for inadequate prescription.






rent admission diagnosis. Just one of those patients had a me-
dical record compatible with UGIB prevention (peptic disease), 
however this patient was not under PPI before admission. Mean 
inpatient time was 9.3 days (SD 6.01) ranging from 1-69 days.
After	 multivariate	 analysis	 through	 logistic	 regression	 (χ2(6) 
=	 47.667,	 p	 <	 0.00,	 with	 the	 model	 explaining	 11.8%	 (Na-
gelkerkeR2)	 of	 the	 variance	and	correctly	classifying	64.2%	of	





Of the 309 episodes inadequately prescribed on admission, 89 
(29%)	received	an	inappropriate	PPI	prescription	on	discharge.	
Just	70	(23%)	cases	had	a	correct	indication	for	taking	this	me-
dication. Univariate analysis (Table 1), compares patients who 
did not receive a PPI prescription on discharge versus patients 
who received and inadequate prescription, regardless of PPI use 
Table 2: Baseline characteristics of 585 inpatient episodes





Motive of admission n (%) 
Lower respiratory tract 
infections 268 (45.8)
Urinary tract infection 70	(12.0)
Heart failure 64 (10.9)
Ischemic stroke 55 (9.4)
Cerebral hemorrhage 8 (1.4)
Other 120 (20.5)
Lenght of stay in days, 
mean	(SD*) 9.3	(6.1)	(95%	CI
† 8.8-9.8)









Selective serotonin reuptake 
inhibitors 61 (10.4)
Type of Indication 70	(100)‡
GERD 6 (8.6)
Peptic Disease 18	(25.7)
H pylori erradication 1 (1.4)
Zollinger-Ellison syndrome 0 (0)
Functional dyspepsia 15 (21.4)
UGIB prevention in the context 
of	NSAID	therapy 17	(24.3)
UGIB prevention in the context 
of antiplatelet therapy 13 (18.6)
*SD:	 standard	deviation;	 †CI:	 confidence	 interval;	 ‡	 total	 n	 is	 superior	 to	
number of patients with indication because some patients had more than 1 
indication for PPI therapy
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during	 inpatient	stay	(n	=	278).	Prior	PPI	use,	 increasing	num-
ber of age and comorbidities were statistically associated with 
PPI prescription for ambulatory care at time of discharge. Due to 
inpatient treatment or diagnosis, two patients gathered indication 
for initiating de novo PPI (one after nosocomial UGI bleed, for 
maintenance therapy, and the other because of the combination 
of chronic corticosteroid treatment for systemic lupus erythema-
tous, antiplatelet treatment and age above 60 years). On mul-
tivariate	analysis,	 through	logistic	regression	(χ2(5)	=	31.549,	p 
<	0.00,	with	the	model	explaining	15.0%	(NagelkerkeR2) of the 
variance	and	correctly	classifying	69.8%	of	cases)	(Table	3)	pre-





described in Table 3.





ted in this patient population because active or subacute UGIBs 
as well as endoscopic procedures are usually admitted to the 
Gastroenterology ward not the IM ward. It is likely that prescrip-
tions would be more accurate in the setting of a Gastroenterology 
ward as previously reported23 both by improved knowledge of 
proper indications as well as increased volume of endoscopic 
procedures and UGIB diagnoses that require PPI initiation.
It was surprising to notice the number of IV prescriptions, nor-
mally used for active UGIB. In our understanding this may be 
due to the overall population in the study, which includes patients 
with decreased oral intake because of old age and comorbidities 
such as previous stroke. It may be argued that these patients 
are less autonomous in the handling of their inpatient medica-
tion if their motor skills are decreased or if they have dysphagia. 
However, it is important to note that not infrequently there were 
other prescriptions (antihypertensive, antidepressants, etc.) by 
oral intake in the same therapeutic sheets of PPI IV prescriptions, 
raising the question of true lack of oral intake. These IV PPI pres-
criptions were naturally deemed inappropriate. The problematic 
of inappropriate IV PPI prescription has been described before 
with Craig et al reporting	up	to	75%	of	inadequate	IV	prescrip-
tions, with proper indications for IV PPI being endoscopic evi-
dence of recent UGIB, patient nil by mouth with a valid indication 
for oral PPI therapy and stress ulcer prophylaxis in a critical care 
setting.23	Another	study	found	that	71%	of	IV	prescriptions	had	




inpatient prescription of a PPI namely female sex, increasing age 
and use of PPI prior to admission (Table 3). Female sex has been 
identified	as	a	predictive	factor	for	IV	PPI	prescription	elsewhe-
re.23 In this study we show that it increases the likelihood of oral 
PPI	as	well	(OR:	0.64	95%	CI:	0.44-0.94,	p	=	0.021).	It	is	unclear	
to us why there is a trend for more prescriptions in the female sex, 
although it could be argued that female patients consult more 







be viewed by physicians as a way for gastric protection. We fou-
nd that the simple fact of being medicated with a PPI prior to ad-
Table 3: Predictors of inappropriate PPI prescription
Variable Odds Ratio 95% Confidence Interval p-value
Predictors of Inappropriate Inpatient PPI Prescription
Female sex 0.64 0.44-0.94 0.021
Age	66-74	years 1.87 1.03-3.38 0.039
Age	≥	75	years 2.22 1.35-3.66 0.002
PPI use prior to admission 3.45 2.07-5.74 0.000
Predictors of Inappropriate discharge PPI Prescription 
Between 4-6 comorbidities 2.05 1.11-3.78 0.022
Between	7-9	comorbidities 4.87 1.73-13.69 0.003
Age	≥	75	years 5.45 1.58-18.79 0.007
117PUBLICAÇÃO TRIMESTRAL VOL.24 | N.º 2 | ABR/JUN 2017
ARTIGOS ORIGINAIS





being medicated prior to admission.26 This raises the question of 
the depth of knowledge from physicians at the time of making the 
therapeutic sheets, at least in what PPIs are concerned. While 
guidelines help establish stress ulcer prophylaxis (SUP) on the 
ICU	setting	(ASHP	–	American	Society	of	Health-System	Phar-
macists), without promotion of PPIs over other options, there are 
no guidelines when it comes to the non-critical care setting, ex-
cept for gastrointestinal diagnosis in need of treatment.1 Despite 
lack	of	evidence	in	this	field,	several	studies	have	demonstrated	
overuse of PPIs. Another reason may come from fear of UGIB 
during inpatient stay.1,	27
On the other hand, lack of complete clinical data in the patien-
ts’	files	due	to	poor	registration	patterns,	patient	frailty,	cognitive	
impairment or inability to verbalize symptoms or prior diagnosis, 
may obscure proper reasons for PPI use, thus mislabeling as 
inappropriate actually appropriate PPI prescriptions. It is still im-
portant to emphasize the need to review the indication for each 
medication prior to its institution during hospital stay and at the 
time of discharge. Talking to relatives or next of kin may aid in 
this process as well as raising awareness of physicians to proper 
registration	of	diagnosis	in	the	patients’	files.
We	evaluated	the	financial	impact	of	inappropriate	PPI	pres-
criptions. Total costs relating solely to inappropriate PPI use as-
cended	to	€1079.96	in	the	three	month	period.	Mean	price	per	
patient per hospital stay was €2.12. These costs are based on 
pricing per pill of oral esomeprazole or IV pantoprazole ampoule 
alone. Consumables such as catheters and syringes were not 
accounted for as well as human resources and possible iatroge-
nic effects of PPI administration. Thus, there are potential savings 
to be made with PPI as far as the inpatient setting is concerned. 
A better description of costs involved can be seen on Table 4.
We also evaluated the pattern of PPI prescription at the time 
of	discharge.	A	2006	study	with	1769	patients	reported	a	22%	
of	 inappropriate	PPI	prescription	for	 inpatient	SUP	with	54%	of	
these patients leaving the hospital under PPI continuation.28 In 
our	study	approximately	29%	(89	of	309)	left	the	hospital	under	
inappropriate	PPI	continuation,	with	just	51	cases	(16.5%)	of	the	
having appropriate reason for PPI continuation. Predictive fac-
tors	of	 inappropriate	discharge	prescription	are	age	≥	75	and	
increasing number of comorbidities as seen on Table 3. Despite 
being	statistically	significant	on	univariate	analysis,	we	did	not	
include prior to admission PPI use in the multivariate analysis for 
discharge prescription, for risk of confounding due to inadver-
ted resuming on of routine medication listed before admission. 
Patient characteristics such as frailty and other polypharmacy in 
these groups may account for the increased number of prescrip-
tions. Also with increasing comorbidities, it is more likely to exist 
some sort of past record of GI diagnosis. In these cases physi-
cians may fear risking recurrence of UGIB in the long haul. This 
may be viewed as lack of proper review of discharge medica-
tion namely the need to maintaining certain medications despite 
appropriate indication. Discharge time should be a privileged 
time for an ambulatory therapeutic review and overlooking it may 
have iatrogenic effects as well as an economic impact. In this 
study we did not propose to evaluate the economic impact of 
inappropriate ambulatory PPI prescription but some studies have 
done so elsewhere.26,29,30 A 4-year long study described a rate of 
69%	of	inappropriate	discharge	PPIs	with	a	related	cost	during	
the	first	30	days	of	up	to	US$3	million.1,26 Another study showed 
that	24.4%	of	patients	were	inadequately	discharged	with	acid	
suppressant therapy with the total cost for unnecessary thera-
py	within	 the	study	period	being	$13973	(US$4.20	per	patient	
each day).26,29 Another 2010 study conducted in an ambulatory 
community	reported	that	among	946	patients	only	35%	had	an	





thout documentation of clinical symptoms reassessment.30
Unfortunately, discharge with an inappropriate PPI prescrip-




pectively, despite having been evaluated by their primary care 
physician.31
An information bias could have been introduced in the study 
since the author’s patients were also enrolled. However, after 
review of the results such bias is residual at best considering 
the proportion of inappropriate prescriptions, meaning that prior 
updated knowledge of guidelines from the authors’ side did not 
interfere with the results.
Table 4: Total costs calculated in the study
Total cost (€)
Indication




Median Minimum Maximum Total
No 2.12 2.97 0.98 0 18.27 1079.96
Yes 2.53 2.48 1.89 0 13.23 192.50
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In this study we did not evaluate whether or not the imple-
mentation of formal guidelines for inpatient prevention of upper 
gastrointestinal bleeding had any impact on the quality of pres-
criptions.	This	has	been	addressed	before	by	Yachimski	et al, 
where the prescription patterns were evaluated before and after 
implementation of guidelines for physicians. The introduction of 
standardized guidelines resulted in an improvement of inpatient 
and discharge prescriptions.17 After release of this study’s resul-
ts, a follow-up interventional study is schedule to begin to assess 
impact on prescriptions. In an era where internists have to ac-
count for a myriad of polypharmacy it is no wonder that strategies 




PPIs remain one of the widest used acid suppressant therapies. 
This study reinforced that inpatient prescription of PPIs is erratic 
both in need and in route of administration. Continuous reinforce-
ment of proper indications for its prescription in the hospitalized 
patient may reduce iatrogenic effects and promote cost savings, a 
statement	due	for	confirmation	in	a	follow-up	interventional	study.	
Clear guidelines for prevention of iatrogenic upper gastrointesti-
nal bleeding in the hospitalized non-ICU patient are still lacking 
but they may result in a more consensual prescription pattern.   ■
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